Moreover, the 36-month beta value for IKT is 1.15. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IKT is 51.26M and currently, short sellers hold a 0.44% of that float. On November 08, 2024, IKT’s average trading volume was 425.49K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IKT) stock’s latest price update
The stock of Inhibikase Therapeutics Inc (NASDAQ: IKT) has increased by 12.59 when compared to last closing price of 2.78. Despite this, the company has experienced a 18.56% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-21 that — IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 — BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company’s common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses. The financing will fund execution of the Phase 2b ‘702′ trial in Pulmonary Arterial Hypertension (PAH) and for general corporate purposes.
IKT’s Market Performance
Inhibikase Therapeutics Inc (IKT) has experienced a 18.56% rise in stock performance for the past week, with a 140.77% rise in the past month, and a 137.12% rise in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 13.71% for IKT. The simple moving average for the last 20 days is 28.81% for IKT stock, with a simple moving average of 73.82% for the last 200 days.
IKT Trading at 81.64% from the 50-Day Moving Average
After a stumble in the market that brought IKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.06% of loss for the given period.
Volatility was left at 13.71%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares surge +114.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +127.91% upper at present.
During the last 5 trading sessions, IKT rose by +19.70%, which changed the moving average for the period of 200-days by +28.46% in comparison to the 20-day moving average, which settled at $2.43. In addition, Inhibikase Therapeutics Inc saw 146.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IKT starting from Bellini Roberto, who purchase 1,460,000 shares at the price of $1.37 back on Oct 21 ’24. After this action, Bellini Roberto now owns 1,460,000 shares of Inhibikase Therapeutics Inc, valued at $2,000,200 using the latest closing price.
Kush Arvind, the Director of Inhibikase Therapeutics Inc, purchase 145,000 shares at $1.37 during a trade that took place back on Oct 21 ’24, which means that Kush Arvind is holding 145,000 shares at $198,650 based on the most recent closing price.
Stock Fundamentals for IKT
Current profitability levels for the company are sitting at:
- -238.85 for the present operating margin
- 0.67 for the gross margin
The net margin for Inhibikase Therapeutics Inc stands at -231.02. The total capital return value is set at -3.71. Equity return is now at value -149.69, with -117.93 for asset returns.
Based on Inhibikase Therapeutics Inc (IKT), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -92.61. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 28.73.
Currently, EBITDA for the company is -19.91 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 2698.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.32.
Conclusion
To wrap up, the performance of Inhibikase Therapeutics Inc (IKT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
